InHANSE Institute of Head and Neck Studies and Education Contact Us


Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy.




Patients will be identified for RAPPER via multi-centre and single site clinical trials and research studies (including qualitative questionnaire-based studies). Patients will be approached by a local research team and asked to provide a blood sample for translational study. Consent will also be sought for collection of family history, long-term follow-up and toxicity data. Patients may also be approached who are not participating in any research activity but who are identified in clinic, either prior to treatment (referred to as ‘prospectively recruited patients’) or during follow-up (referred to as ‘retrospectively recruited patients’), by an investigator involved in RAPPER.

Eligibility Criteria

Inclusion Criteria

• Patients receiving, or who have received, potentially curative radiotherapy for cancer (including but not limited to breast, prostate, gynaecological, oesophageal, rectal, lung, head and neck cancer and sarcoma).

• Appropriate patient consent.

• Patients able to provide a venous blood sample.

• No other malignancy prior to treatment for the specified tumour types except basal cell or squamous cell carcinoma of the skin, or in situ carcinoma.

Exclusion Criteria

• Patients who are in poor health due to cancer or non-cancer related conditions.

• Patients who are unable to give informed consent or a blood sample.



Lead Centre:

University of Manchester

Study Coordinator:

Rebecca Elliott
Christie Hospital NHS Foundation Trust
550 Wilmslow Road
Greater Manchester
M20 4BX

Tel: 0161 446 3045
Fax: 0161 446 8111

Charity appeal

Find out more about our £1m Charity appeal for the AcceleraTED cancer Treatment programme.